The research, led by Xiaoli Xie, Delin Tan, Jingyun Mo and colleagues under the supervision of Huiqing Jiang, Tingting Li and Jia Wang, set out to address a conspicuous gap in cancer genomics. While alterations in three-dimensional chromosome organization—topologically associating domains, chromatin loops and A/B compartments—are well documented in many tumors, the behavior of the X chromosome itself during carcinogenesis has attracted remarkably little attention. Yet the X chromosome carries more than 800 genes, many involved in cell proliferation, metabolism and immune regulation, and liver disease is notorious for its pronounced sex bias: men face a substantially higher risk of hepatocellular carcinoma than women, a pattern the team suspected might be written into the architecture of the sex chromosomes.

To follow genomic architecture across disease progression, the researchers built what they describe as a 4D nucleome landscape, combining chromosome conformation capture technologies such as Hi-C with ChIP-seq, RNA-seq, whole-genome sequencing and DNA methylation profiling, sampled at multiple time points as chemically induced liver disease unfolded in mice. Using F1 hybrid mice, in which the two parental X chromosomes can be distinguished by allele-specific sequence variants, the team could separate the folding of the single active X chromosome in males from the paired active and inactive X chromosomes in females. This allelic resolution proved critical, because it exposed a striking asymmetry: the conformational changes and gene activation occurring on the male active X chromosome during hepatocarcinogenesis were far more pronounced than those on the female active X chromosome, mirroring the male bias seen in human liver disease.

The most surprising finding emerged when the team turned to human hepatic tissue. In normal liver samples from both men and women, the active X chromosome is not organized as a single continuous domain but is split into two large mega-domains separated by a defined boundary located near the 90-megabase region of the chromosome. This bipartite configuration is specific to the liver—it was not observed in other tissues such as colon and lung—and, notably, it appears largely independent of the polyploid state of hepatocytes, which commonly carry doubled or quadrupled genome copies without ill effect. The bipartite active X chromosome, in other words, is a liver-specific architectural feature, maintained even in cells with unusual ploidy.

That stability, however, collapses early in disease. Analyzing fibrotic, cirrhotic and tumoral liver tissue from patients of both sexes, the researchers found that the mega-domain boundary weakens and the two halves of the active X chromosome merge into a single, unified domain. The merging is not merely a passive byproduct of genomic chaos in tumors. When the two halves fuse, the strengthened long-range contacts between them occur predominantly between A-type, active compartments, and these new A–A interactions are associated with the activation of X-linked genes. Genes on the X chromosome were among the most disproportionately upregulated in hepatocellular carcinoma samples, a pattern confirmed in data from The Cancer Genome Atlas, where the ratio of upregulated to total genes on the X chromosome ranked at or near the top in male tumors.

To establish causality rather than correlation, the team employed CRISPR–Cas3, a genome-editing system capable of deleting megabase-scale stretches of DNA that standard Cas9 cannot handle. By excising the boundary element that separates the two mega-domains of the active X chromosome, the researchers recreated, in isolation, the architectural event that accompanies liver cancer. The result was unambiguous: disruption of the bipartite conformation alone was sufficient to trigger a premalignant transition. In liver organoids, boundary deletion transformed normally cystic structures into thickened, compact spheroids reminiscent of early tumor growth, accompanied by the activation of X-linked genes. The boundary, it seems, functions as a tumor-suppressive architectural element whose loss unlocks oncogenic expression programs.

Having demonstrated that structural dissolution drives malignant change, the researchers then asked which of the activated X-linked genes actually matter for liver cancer. Using complementary CRISPR-based screening approaches—CRISPRa to boost the expression of genes that were weakly expressed, and CRISPRi to silence genes that were highly expressed—the team winnowed the long list of upregulated X-linked genes down to a set of functional drivers in hepatocellular carcinoma, including metabolic and stress-response genes such as G6PD and members of the ARMCX family. The identification of these effective genes provides a bridge between an abstract chromosomal conformation and concrete molecular targets that could, in principle, be therapeutically interrogated.

The study’s technical scope is considerable. The raw data, encompassing Hi-C, ChIP-seq, RNA-seq, whole-genome sequencing and bisulfite sequencing from both mouse and human samples, have been deposited in public archives, and all analysis code has been released through GitHub and Zenodo. Genome-wide, the researchers also documented the broader erosion of liver genome organization during carcinogenesis: topologically associating domains weakened, CTCF and H3K27ac signals at boundaries diminished, chromatin loops faded, and DNA methylation increased. Against this backdrop of global architectural decay, the specific, boundary-dependent dissolution of the bipartite active X chromosome stands out as an unusually discrete and mechanistically tractable event—one of the earliest and most consistent architectural signatures of hepatocarcinogenesis in both mice and humans.

The findings also carry implications for the long-standing puzzle of sex bias in liver cancer. Because males possess only a single X chromosome, every hepatocyte depends entirely on the architectural integrity of that one active X for proper dosage regulation of X-linked genes. The more pronounced conformational disruption and gene activation observed on the male X during disease progression offers a structural explanation for why male livers appear more vulnerable to malignant transformation, complementing earlier hypotheses about tumor-suppressor genes that escape X inactivation. Intriguingly, the work resonates with prior studies showing that the inactive X chromosome also folds into a bipartite structure in mice—one organized around the macroH2A-rich DXZ4-like boundary—suggesting that bipartite architecture may be a general feature of X chromosome biology whose functions differ profoundly between the active and inactive states.

For the field of cancer genomics, the message is that the fourth dimension of the genome—its behavior across time and disease states—can reveal vulnerabilities invisible to static snapshots. A liver-specific, megabase-scale boundary on the active X chromosome emerges from this study as both an early casualty of hepatocarcinogenesis and a functional guardian against it. If confirmed and extended, monitoring the integrity of this bipartite structure, or the X-linked genes it restrains, could eventually inform risk stratification in patients with chronic liver disease, while the boundary itself and the genes it controls offer fresh mechanistic entry points into one of the world’s deadliest cancers.

Subject of Research: Dissolution of the bipartite active X chromosome structure during hepatocellular carcinoma development

Article Title: 4D nucleome landscape reveals dissolution of bipartite active X chromosome in liver cancer development

Article References: 4D nucleome landscape reveals dissolution of bipartite active X chromosome in liver cancer development. (n.d.). https://doi.org/10.1038/s41556-026-02063-y

Image Credits: AI Generated

DOI: 10.1038/s41556-026-02063-y

Keywords: X chromosome, 4D nucleome, hepatocellular carcinoma, genome architecture, Hi-C, bipartite mega-domain, liver fibrosis, CRISPR-Cas3, X-linked gene activation, sex bias in cancer, chromatin loops, premalignant transformation

Hepatocellular carcinoma is notorious for its poor prognosis and resistance to conventional therapies, mainly due to its ability to evade the immune system. Immune checkpoint molecules like PD-L1 are expressed on cancer cells to inhibit T-cell activity, effectively turning off the body’s natural anti-tumor response. While PD-L1’s role in immune escape is well established, the upstream regulatory mechanisms controlling its abnormal expression within HCC remained elusive—until now. The identification of LMNB2 as a transcriptional enhancer of PD-L1 unlocks a new layer of complexity in tumor immunology.

At the heart of this discovery is the function of LMNB2 beyond its canonical structural role. Typically, lamin proteins including LMNB2 are components of the nuclear lamina, providing mechanical support to the nucleus and contributing to gene expression regulation via chromatin interactions. The study reveals that LMNB2 directly modulates PD-L1 gene transcription, an effect previously unrecognized. Using extensive molecular and genomic assays, the authors demonstrate that elevated levels of LMNB2 correlate with increased PD-L1 mRNA and protein in HCC cells, suggesting a transcriptional regulatory axis.

The mechanistic insights were unveiled through a combination of chromatin immunoprecipitation sequencing (ChIP-seq) and reporter assays. These experiments showed that LMNB2 localizes to the promoter region of the PD-L1 gene, facilitating an open chromatin configuration conducive to transcription. Moreover, LMNB2 interacts with key transcription factors and epigenetic modifiers, orchestrating a transcriptional environment that upregulates PD-L1 expression. This mechanistic clarity not only establishes LMNB2’s novel function but also highlights potential molecular targets for disrupting the immune escape pathway.

Intriguingly, the authors demonstrated that silencing LMNB2 expression via RNA interference led to substantial reductions in PD-L1 levels, both at the transcript and protein scale. This effect sensitized HCC cells to cytotoxic T lymphocyte (CTL)-mediated killing, indicating that LMNB2 contributes functionally to immune evasion. In vivo tumor models reinforced these findings: LMNB2-depleted tumors exhibited diminished growth rates and increased immune infiltration compared to controls, underscoring the therapeutic potential of targeting this axis.

This research thus positions LMNB2 not merely as a bystander structural protein but as a critical regulator of immune checkpoint expression, redefining our understanding of nuclear lamina proteins in cancer biology. The implications are vast. Targeting LMNB2 or its associated cofactors could potentiate existing immunotherapies—such as PD-1/PD-L1 checkpoint inhibitors—by lowering PD-L1 expression and improving immune-mediated tumor clearance in HCC patients, where response rates to immunotherapy remain suboptimal.

Moreover, the study contextualizes LMNB2 in hepatocarcinogenesis by analyzing clinical specimens. Patient samples with advanced-stage HCC showed significantly elevated LMNB2 and PD-L1 expression, correlating with poor prognosis and reduced overall survival. This clinical correlation validates the laboratory findings and suggests that testing for LMNB2 expression might serve as a biomarker for immune escape propensity and therapy responsiveness.

From an oncogenic signaling perspective, LMNB2’s regulation of PD-L1 integrates with known pathways such as STAT3, NF-κB, and HIF-1α, which stimulate PD-L1 transcription under various tumor microenvironmental stresses. The study proposes that LMNB2 functions as a nodal point amplifying transcriptional outputs across these signaling routes, hence orchestrating a robust immunosuppressive phenotype crucial for tumor progression.

In addition to transcriptional regulation, the researchers explored the structural and epigenetic dynamics modulated by LMNB2. It appears that LMNB2-mediated chromatin remodeling creates a permissive context for PD-L1 expression by reducing nucleosome density and facilitating enhancer-promoter looping. This spatial chromatin remodeling adds a layer of epigenetic control, emphasizing the sophisticated regulation of immune checkpoints in cancer.

Therapeutically, the study advocates for LMNB2 inhibitors or molecules disrupting its interactions with transcriptional machinery as potential adjuncts to immunotherapy. While no specific LMNB2-targeted drugs currently exist, repurposing epigenetic modulators or developing peptides to interfere with LMNB2’s nuclear functions could be promising. Early-stage preclinical models combining LMNB2 suppression with anti-PD-1 antibodies exhibited synergistic tumor regression, highlighting the translational potential.

The research also encourages a reevaluation of nuclear lamina proteins in cancer beyond traditional structural roles. It suggests that other lamin family members might similarly regulate oncogenic transcription programs, broadening the horizon for nuclear envelope-targeted cancer therapies. These findings urge the scientific community to explore nuclear architecture as a dynamic participant in tumor immunity and chromatin biology.

Immunologically, disrupting LMNB2-mediated PD-L1 upregulation may restore robust T-cell effector functions, enhancing antigen-specific responses vital for tumor eradication. This aligns with the broader paradigm shift in oncology, prioritizing immune microenvironment reprogramming over direct cytotoxicity. The study therefore adds a valuable component to the evolving arsenal of immunomodulatory strategies.

In summary, Li, Zhu, and Zhai’s work uncovers a novel and unexpected role of LMNB2 in driving immune escape in hepatocellular carcinoma through PD-L1 transcriptional activation. This dual role of LMNB2—as both a nuclear structure protein and an immune checkpoint regulator—redefines its biological significance and opens new therapeutic avenues to enhance the efficacy of immunotherapies in liver cancer. As the field races to develop more effective treatments, this insight offers a beacon of hope for tackling the immune evasiveness of this devastating cancer.

Subject of Research: The regulatory role of LMNB2 in PD-L1 transcription and immune escape mechanisms in hepatocellular carcinoma.

Article Title: LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma.

Article References:
Li, Y., Zhu, J., Zhai, F. et al. LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma. Cell Death Discov. 11, 269 (2025). https://doi.org/10.1038/s41420-025-02540-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02540-7